19 results match your criteria: "Centre de Référence MCGRE[Affiliation]"

Predictors of health-related quality of life in a large cohort of adult patients living with sickle cell disease in France: the DREPAtient study.

Front Public Health

June 2024

Patient-Reported Outcomes Research (PROQOL), Unité de Recherche Clinique en Economie de la Santé (URC-ECO), Hôpital Hôtel-Dieu, AP-HP, Paris, France.

Background: Sickle cell disease (SCD) is an inherited autosomal recessive disorder exhibiting a range of symptoms and acute and/or chronic complications that affect the quality of life. This study aimed to assess health-related quality of life (HRQoL) and to identify the associated factors in adult patients with SCD in France.

Methods: DREPAtient is a cross-sectional, multicenter study conducted from June 2020 to April 2021 in France and in certain French overseas territories where SCD is highly prevalent.

View Article and Find Full Text PDF

While sickle cell anemia (SCA) and hereditary spherocytosis (HS) share common features of increased spleen erythrophagocytosis due to increased red blood cell (RBC) turnover, SCA is specifically characterized by susceptibility to infections. In this study, histological lesions in the spleens of pediatric patients with SCA were analyzed, in close correlation with past clinical history and comparatively to HS, healthy and transfused β-thalassemia patients (TDT). An evaluation of red pulp elementary lesions (red pulp fibrosis, iron deposition, number of Gandy-Gamna, and RBC trapping) combined into a severity score was established, as well as B-cell follicles analysis.

View Article and Find Full Text PDF

Pubertal development of transfusion-dependent thalassemia patients in the era of oral chelation with deferasirox: results from the French registry.

Haematologica

July 2024

Service d'Hematologie, Immunologie et Oncologie Pediatrique, Hopital La Timone Enfants, AP-HM, Marseille, France; Centre de Reference MCGRE, Service d'Hematologie, Immunologie et Oncologie Pediatrique, Hopital La Timone Enfants, AP-HM, Marseille.

View Article and Find Full Text PDF

Hydroxyurea is associated with later onset of acute splenic sequestration crisis in sickle cell disease: Lessons from the European Sickle Cell Disease Cohort-Hydroxyurea (ESCORT-HU) study.

Am J Hematol

April 2024

Department of General Pediatrics and Pediatric Infectious Diseases, Reference Center for Sickle Cell Disease, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.

Acute splenic sequestration crisis (ASSC) is a potentially life-threatening complication of sickle cell disease (SCD), typically occurring in young patients under 5 years of age, with a median age at first episode of less than 2 years. Because a beneficial effect of hydroxyurea (HU) on spleen perfusion and splenic function has been suspected, we hypothesized that HU treatment might be associated with later onset of ASSC in patients with SCD. To investigate this hypothesis, we analyzed data from the ESCORT-HU study on a large cohort of patients with SCD receiving HU, enrolled between January 2009 and June 2017 with a follow-up of 7309 patient-years of observation.

View Article and Find Full Text PDF

Global burden of sickle cell disease in 2021.

Lancet Haematol

October 2023

School of Cancer and Pharmaceutical Sciences, King's College London, London, UK; Department of Paediatric Haematology, King's College Hospital NHS Foundation Trust, London, UK.

View Article and Find Full Text PDF

[Management of acute complications of sickle cell disease].

Rev Prat

May 2023

Service de médecine interne Oncopole, Centre de référence des maladies constitutionnelles du globule rouge, filière MCGRE, CHU de Toulouse, Toulouse, France.

MANAGEMENT OF ACUTE COMPLICATIONS OF SICKLE CELL DISEASE. Acute complications are the most frequent causes of hospitalization and morbidity in patients with sickle cell disease. Vaso-occlusive crisis are responsible of more than 90% of hospitalization, but numerous acute complications can affect multiples organ or function, that may be life-threatening.

View Article and Find Full Text PDF

[Improve education of physicians and other caregivers about sickle cell disease].

Rev Prat

May 2023

Université Paris-Cité, France . AP-HP, Hôpital européen Georges-Pompidou, service de médecine interne, Centre national de référence drépanocytose, thalassémie, et autres maladies rares des globules rouges et de l'érythropoïèse, Paris, France.

View Article and Find Full Text PDF

Early splenectomy in a large cohort of children with sickle cell anemia: risks and consequences.

Haematologica

December 2023

Centre de Référence MCGRE, Service d'Hématologie-Immunologie, AP-HP, Hôpital Robert Debré, F-75019 Paris, France; Université Paris Cité and Université des Antilles, Inserm, BIGR, F-75015 Paris.

In children with sickle cell anemia (SCA), early splenic complications can require splenectomy, but the benefit-to-risk ratio and the age at which splenectomy may be safely performed remain unclear. To address this question, we analyzed the rate of post-splenectomy events in children with SCA splenectomized between 2000-2018 at the Robert Debré University Hospital, Paris, France. A total of 188 children underwent splenectomy, including 101 (11.

View Article and Find Full Text PDF

Severity and burden of sickle cell disease in France: a nationwide real-world study.

Haematologica

September 2023

Sickle Cell Referral Center, Henri Mondor Hospital, AP-HP, UPEC, Laboratory of Excellence GR-Ex, INSERM Unit 955, Mondor Institute of Biomedical Research, Paris-Est Creteil University, Creteil.

The burden of sickle cell disease (SCD) in France has been difficult to apprehend due to the paucity of reliable nationwide epidemiological data. We aimed to describe the epidemiology of SCD and evaluate its burden and costs. Patients with SCD and most severely affected patients were identified between 2012 and 2018 from the French National Health Data System database (SNDS, Système national des données de santé).

View Article and Find Full Text PDF

β-Thalassemia in childhood: Current state of health in a high-income country.

Br J Haematol

April 2023

National Thalassemia Registry (NaThalY), Service de Génétique, Hôpital La Timone Enfants, APHM, Marseille, France.

β-thalassemia is an haemoglobinopathy characterized by a defective synthesis of the β-globin chain. To assess the current state of health of paediatric patients with β-thalassemia, data from the French national registry regarding children born between 2005 and 2020 with β-thalassemia intermedia (TI) or major (TM) were collected. A total of 237 patients (median age 7.

View Article and Find Full Text PDF

Splenectomy in sickle cell disease: do benefits outweigh risks?

Haematologica

April 2023

Centre de Référence MCGRE, Service d'Hématologie-Immunologie, AP-HP, Hôpital Robert Debré, F-75019 Paris, France; Université Paris Cité and Université des Antilles, Inserm, BIGR, F-75015 Paris.

View Article and Find Full Text PDF

Determinants of severity in sickle cell disease.

Blood Rev

November 2022

Department of Paediatric Haematology, King's College Hospital, and School of Cancer and Pharmaceutical Science, King's College, London, UK. Electronic address:

Sickle cell disease is a very variable condition, with outcomes ranging from death in childhood to living relatively symptom free into the 8 decade. Much of this variability is unexplained. The co-inheritance of α thalassaemia and factors determining HbF levels significantly modify the phenotype, but few other significant genetic variants have been identified, despite extensive studies.

View Article and Find Full Text PDF

Hereditary xerocytosis is a rare red blood cell disease related to gain-of-function mutations in the FAM38A gene, encoding PIEZO1, in 90% of cases; PIEZO1 is a broadly expressed mechano-transducer that plays a major role in many cell systems and tissues that respond to mechanical stress. In erythrocytes, PIEZO1 adapts the intracellular ionic content and cell hydration status to the mechanical constraints induced by the environment. Until recently, the pathophysiology of hereditary xerocytosis was mainly believed to be based on the "PIEZO1-Gardos channel axis" in erythrocytes, according to which PIEZO1-activating mutations induce a calcium influx that secondarily activates the Gardos channel, leading to potassium and water efflux and subsequently to red blood cell dehydration.

View Article and Find Full Text PDF

Rapid Gardos Hereditary Xerocytosis Diagnosis in 8 Families Using Reticulocyte Indices.

Front Physiol

January 2021

Service d'Hématologie Biologique, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France.

Gardos channelopathy (Gardos-HX) or type 2 stomatocytosis/xerocytosis is a hereditary hemolytic anemia due to mutations in the gene. It is rarer than inherited type 1 xerocytosis due to mutations (Piezo1-HX) and its diagnosis is difficult given the absence of a specific clinical or biological phenotype. We report here that this diagnosis can be sped up using red blood cell (RBC) indices performed on an ADVIA 2120 (Siemens) analyzer, which measures reticulocyte mean corpuscular volume (rMCV) and mean corpuscular hemoglobin concentration (rMCHC).

View Article and Find Full Text PDF

Impact of renal function on hydroxyurea exposure in sickle-cell disease patients.

Br J Clin Pharmacol

May 2021

Centre de référence pour les syndromes drépanocytaires majeurs, AP-HP, Hôpitaux Universitaires Henri Mondor, Université Paris Est-Créteil, Créteil, France.

Aims: This prospective study aimed to develop a population pharmacokinetics (PK) model of hydroxyurea (HU) in patients with sickle cell disease. This model can be used to determine the impact of glomerular filtration rate (GFR) on HU kinetics.

Methods: We included 30 patients.

View Article and Find Full Text PDF

How I Treat Acute Chest Syndrome in Asthmatic Children with Sickle Cell Disease. A Practical Review.

Hemoglobin

September 2020

Service de Médecine et Chirurgie Pédiatrique, Centre Hospitalier de Cayenne, Cayenne Cedex, Guyanne Française.

Asthma is associated with increased rate of acute chest syndrome (ACS), pain episodes and premature death. Differentiating between an acute asthma exacerbation and ACS is a challenge clinically as they can present with similar symptoms. Clinicians should be aware of symptoms of asthma or broncho spasm in any children with sickle cell disease, as adequate treatments are required.

View Article and Find Full Text PDF
Article Synopsis
  • - The study analyzed 126 individuals from 64 families with hereditary xerocytosis, revealing various clinical, hematologic, and genetic characteristics including specific mutations like p.Arg352His and new probable pathogenic variations.
  • - Key symptoms for diagnosis included persistent hemolysis after spleen removal and increased ferritin levels, along with significant risk factors for thrombotic events post-splenectomy and severe anemia in related disorders, which differ from hereditary xerocytosis.
  • - Findings highlight that hereditary xerocytosis and Gardos channelopathy are distinct conditions with shared features like hemolysis and iron overload, emphasizing the need for improved diagnosis and management strategies for affected patients.
View Article and Find Full Text PDF